1-13 of 13
Eric Qiong Wu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Annie Guerin, MSc, Cindy Revol, MPH, Agnihotram V. Ramanakumar, PhD, Rebekah Foster, BA, Eric Qiong Wu, PhD, Shivani K Mhatre, MSc, Lei Chen, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1304.
https://doi.org/10.1182/blood.V124.21.1304.1304
Published: 2014
Journal Articles

Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up

Lei Chen, MD, PhD, Annie Guerin, MSc, Maryna Marynchenko, MBA, Raluca Ionescu-Ittu, PhD, Robert Hiscock, MSc, Roy Nitulescu, MA, Chopra Pooja, MSc, Ling-I Hsu, MPH, Christopher Keir, MD, Eric Qiong Wu, PhD
Journal: Blood
Blood (2013) 122 (21): 4038.
https://doi.org/10.1182/blood.V122.21.4038.4038
Published: 2013
Journal Articles

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.

Daniel J. DeAngelo, MD, PhD, Lei Chen, MD, PhD, Annie Guerin, MSc, Amy Styles, MSc, Clemence Aberki, BSc, Philippe Giguere-Duval, BSc, Eric Qiong Wu, PhD
Journal: Blood
Blood (2012) 120 (21): 2792.
https://doi.org/10.1182/blood.V120.21.2792.2792
Published: 2012
Journal Articles

Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy.

James D. Griffin, MD, Annie Guerin, MSc, Lei Chen, MD, PhD, Alexander R. Macalalad, MD, Jiayuan Luo, MSc, Eric Qiong Wu, PhD
Journal: Blood
Blood (2012) 120 (21): 2796.
https://doi.org/10.1182/blood.V120.21.2796.2796
Published: 2012
Journal Articles

Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey

Stuart L. Goldberg, MD, Lei Chen, MD, PhD, Solveig G. Ericson, MD, PhD, Alexander R. Macalalad, MD, Annie Guerin, MSc, Nathan Liu, MPH, Michael Kaminsky, BSc, Eric Qiong Wu, PhD
Journal: Blood
Blood (2012) 120 (21): 1685.
https://doi.org/10.1182/blood.V120.21.1685.1685
Published: 2012
Journal Articles

Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD
Journal: Blood
Blood (2012) 120 (21): 4447.
https://doi.org/10.1182/blood.V120.21.4447.4447
Published: 2012
Journal Articles

Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib As Second-Line Therapy

Alexander R. Macalalad, MD, Lei Chen, MD, PhD, Annie Guerin, MSc, Jiayuan Luo, MSc, Eric Qiong Wu, PhD, James D. Griffin, MD
Journal: Blood
Blood (2012) 120 (21): 4443.
https://doi.org/10.1182/blood.V120.21.4443.4443
Published: 2012
Journal Articles

Comparison of Adherence Between Nilotinib and Dasatinib As Second-Line Therapies in Chronic Myeloid Leukemia

Annie Guerin, MSc, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Michael Stepner, BA, James D Griffin, MD, Eric Qiong Wu, PhD
Journal: Blood
Blood (2011) 118 (21): 2754.
https://doi.org/10.1182/blood.V118.21.2754.2754
Published: 2011
Journal Articles

Comparison of Adherence Between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia.

Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Amy Guo, PhD, James D. Griffin, MD, Andrew Peng Yu, PhD, Eric Qiong Wu, PhD
Journal: Blood
Blood (2010) 116 (21): 3437.
https://doi.org/10.1182/blood.V116.21.3437.3437
Published: 2010
Journal Articles

The Economic Burden of Pleural Effusions (PE) In Patients with Chronic Myeloid Leukemia (CML).

Eric Qiong Wu, PhD, Annie Guerin, MSc, Vamsi Bollu, PhD, MBA, Denise Williams, MD, Amy Guo, PhD, Diego Ponce de Leon Barido, BA, BS, Andrew Peng Yu, PhD, Alfonso Quintás-Cardama, MD
Journal: Blood
Blood (2010) 116 (21): 3841.
https://doi.org/10.1182/blood.V116.21.3841.3841
Published: 2010
Journal Articles

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Andrew Peng Yu, PhD, Arielle G Bensimon, BA, Maryna Marynchenko, MBA, Eric Qiong Wu, PhD, Madhav Namjoshi, PhD, Amy Guo, PhD, Solveig G Ericson, MD, PhD, Noopur Raje, MD
Journal: Blood
Blood (2010) 116 (21): 1956.
https://doi.org/10.1182/blood.V116.21.1956.1956
Published: 2010
Journal Articles

Non-Adherence to Imatinib in Chronic Myeloid Leukemia Patients Is Associated with a Short Term and Long Term Negative Impact On Healthcare Utilization and Costs.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Andrew Peng Yu, PhD, Andres Sirulnik, MD, PhD, James D Griffin, MD
Journal: Blood
Blood (2009) 114 (22): 4270.
https://doi.org/10.1182/blood.V114.22.4270.4270
Published: 2009
Journal Articles

Comparison of Healthcare Utilization and Costs Between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia.

Eric Qiong Wu, PhD, Vamsi K Bollu, PhD, MBA, Amy Guo, PhD, Annie Guerin, MSc, Magda Tsaneva, BA, Denise Williams, MD, James D Griffin, MD
Journal: Blood
Blood (2009) 114 (22): 4286.
https://doi.org/10.1182/blood.V114.22.4286.4286
Published: 2009